Gyre Therapeutics, Inc. (GYRE) Total liabilities 2017–2025
Gyre Therapeutics, Inc. (GYRE) total liabilities at each fiscal year-end, per SEC filings.
$31.4MFY2025 · since FY2017: $8.7M → $31.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $31.4M | +16.3% |
| FY2024 | $27.0M | -29.1% |
| FY2023 | $38.1M | +203.6% |
| FY2022 | $12.5M | -14.0% |
| FY2021 | $14.6M | -22.4% |
| FY2020 | $18.8M | — |
| FY2018 | $5.0M | -43.1% |
| FY2017 | $8.7M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating marginGYRE Operating cash flowGYRE Free cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Shareholders’ equityGYRE overview →